SS-31 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
SS-31 is available as a research compound from several vetted suppliers. When sourcing SS-31, prioritize vendors with third-party certificates of analysis (COA), HPLC purity testing above 98%, and proper cold-chain shipping.
Where Can You Buy SS-31?
SS-31 is fda-approved september 2025 (forzinity) for barth syndrome. phase 3 trials ongoing for other indications. It is available from several research chemical suppliers. The quality difference between vendors is significant — sourcing from a tested, reputable supplier is the single most important decision.
What Should You Look For in a SS-31 Vendor?
Third-party COA testing: Every batch should come with a Certificate of Analysis from an independent lab confirming identity and purity (98%+ HPLC).
Cold-chain shipping: Peptides degrade in heat. Quality vendors use insulated packaging and cold packs.
Proper packaging: Lyophilized powder in sealed, labeled vials. Avoid pre-mixed or pre-loaded products.
Reputation: Established vendors with consistent community feedback are safer than new or untested sources.
Which Vendors Carry SS-31?
WolveStack has reviewed the following suppliers for purity, COA availability, shipping practices, and community reputation. These are the vendors we recommend for sourcing research-grade SS-31.
What Red Flags Should You Watch For?
No COA: If a vendor can't provide a current, third-party COA for their SS-31, move on. This is non-negotiable.
Unusually low prices: Peptide synthesis is expensive. Prices dramatically below market average usually indicate underdosed or substituted product.
Pre-mixed solutions: Reconstituted peptides have a shelf life of 4-6 weeks. Vendors selling pre-mixed SS-31 in syringes or vials are shipping degraded product.
No contact/return policy: Legitimate vendors stand behind their products.
How Should You Store SS-31 After Purchase?
Unreconstituted SS-31 (lyophilized powder): Store at -20°C (freezer) for up to 12+ months. Keep sealed and away from moisture.
Reconstituted SS-31: Store at 2-8°C (refrigerator). Use within 4-6 weeks. Never freeze reconstituted peptides.
Bottom Line on Buying SS-31
Source SS-31 from vendors with current third-party COA testing, cold-chain shipping, and established reputations. Quality directly determines results — cheap peptides are expensive mistakes.
Complete Guide
SS-31 (Elamipretide) : Mitochondrial Peptide for Energy & Aging
Related Reading
- SS-31 Dosage Guide
- SS-31 Benefits
- SS-31 Side Effects
- SS-31 Stacking Guide
- SS-31 Cycle Guide
- SS-31 Research
Calculate Your SS-31 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for SS-31.
Open Calculator →Research-Grade Sourcing
If you're going to research SS-31, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What is the recommended SS-31 dosage?
Common dosages: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Cycle length: 12-48 weeks in clinical trials. Half-life: approximately 20-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Is SS-31 safe?
SS-31 has shown a favorable safety profile in research. FDA-approved September 2025 (FORZINITY) for Barth syndrome. Phase 3 trials ongoing for other indications. All research should follow appropriate safety protocols.